Erik Lundgren
multiple sclerosis

Immunic CEO: “We want to understand MS patients better than anyone”

,

Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy is vidofludimus calcium, an oral therapy being developed for relapsing and progressive MS. European Biotech spoke with Immunic’s CEO Erik Lundgren about the company’s clinical trials and commercial ambitions, the role of neuroprotection and why he believes the next major opportunity in MS may lie beyond relapse control.

Read more
spain map pushpin location
Watchlist

Six Spanish biotech ­startups to watch in 2026

,

The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, while 39 new biotech firms were created in 2025.

Read more
cell with receptors
drug delivery

Cell therapies: breaking ­barriers in ­solid tumours

,

It’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable­ ­therapy against tumours. But when it comes to fighting solid tumours, CAR-Ts rapidly show their limits. A new generation of cancer cell therapies could set new standards and change the way we think about drug delivery in solid tumours.

Read more
Strüngmann Award 2026
Entrepreneurship

The Strüngmann legacy, passed on

,

Thomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family office, an award bearing their name is turning that investment philosophy into a search for Europe’s next biotech builders.

Read more
Headquarter in Mainz, GermanyBioNTech SE
Oncology

BioNTech adds clinical weight to its oncology pivot at WCLC 2026

,

New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals can translate into registrational success.

Read more
exosome cellular mechanism
Drug delivery

Inside exosomes: Nature’s drug carriers

,

Next-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle ­remains ­targeted delivery: avoiding immune ­reactions (seen with many viral vectors) or undesired organ accumulation (evidenced with LNPs in the liver). Scientists are now harnessing a technology that could overcome these hurdles by using ­vesicles that cells naturally produce: exosomes.

Read more
brain network connections
Neurology

How biotech is treating epilepsy beyond seizures

,

For decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and cell therapies reshape the field, epilepsy is being redefined as many diseases with deeper biological roots.

Read more
Marco Ravot-Licheri, Head of Digital – Life Sciences Business at TecanTecan
Lab automation

The emergence of agentic AI in lab automation

, ,

There’s uncertainty and concern about whether AI will replace humans in workplaces. But Marco Ravot-Licheri, Head of Digital – Life Sciences Business at Tecan, told us that AI could increase laboratory productivity and make research more meaningful.

Read more
maze arrow shortcut
Regulatory

Fast-track trial approval: a way to jump the EU queue?

,

Launched in 2022, the EU Clinical Trials Information System (CTIS) aims to streamline and centralise the process of applying for clinical trial authorisation, but has also increased typical approval timelines. Several nations are now introducing accelerated pathways that jump the queue, offering one of the fastest routes to the clinic in the world for companies navigating this increasingly complex regulatory landscape.

Read more
A microscopic view of small interfering RNA molecules binding to mRNA demonstrating the epigenetic mechanism of RNA interference in gene silencing
Technologies

RNA medicine enters its ­second act

,

The COVID-19 pandemic transformed RNA technologies into one of the most ­visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing capability and global deployment, pushing RNA therapeutics into the public spotlight. But ­according to companies working in the field, the ­pandemic was not the beginning of the RNA ­story. Instead, it accelerated technologies that had already been under development for years.

Read more